Financial - Conglomerates
Build Your Comparison
Side-by-side financial analysisStock Comparison
ACOG vs LLY
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - General
ACOG vs LLY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Financial - Conglomerates | Drug Manufacturers - General |
| Market Cap | $98M | $1.07T |
| Revenue (TTM) | $11M | $72.25B |
| Net Income (TTM) | $-25M | $25.27B |
| Gross Margin | 86.4% | 83.5% |
| Operating Margin | -250.1% | 45.9% |
| Forward P/E | — | 30.9x |
| Total Debt | $0.00 | $42.50B |
| Cash & Equiv. | $66M | $7.16B |
ACOG vs LLY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 24 | Jun 26 | Return |
|---|---|---|---|
| Alpha Cognition Inc… (ACOG) | 100 | 95.2 | -4.8% |
| Eli Lilly and Compa… (LLY) | 100 | 142.5 | +42.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACOG vs LLY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
In this particular matchup, ACOG is outpaced on most metrics by others in the set.
LLY carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 11 yrs, beta 0.53, yield 0.5%
- Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
- 14.8% 10Y total return vs ACOG's -11.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 44.7% revenue growth vs ACOG's -116.5% | |
| Quality / Margins | 35.0% margin vs ACOG's -232.2% | |
| Stability / Safety | Beta 0.53 vs ACOG's 1.29 | |
| Dividends | 0.5% yield; 11-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +40.3% vs ACOG's -34.4% | |
| Efficiency (ROA) | 22.7% ROA vs ACOG's -41.8%, ROIC 41.8% vs -32.4% |
ACOG vs LLY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ACOG vs LLY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
LLY leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
LLY is the larger business by revenue, generating $72.2B annually — 6674.1x ACOG's $11M. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to ACOG's -2.3%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $11M | $72.2B |
| EBITDAEarnings before interest/tax | -$27M | $34.7B |
| Net IncomeAfter-tax profit | -$25M | $25.3B |
| Free Cash FlowCash after capex | -$30M | $13.6B |
| Gross MarginGross profit ÷ Revenue | +86.4% | +83.5% |
| Operating MarginEBIT ÷ Revenue | -2.5% | +45.9% |
| Net MarginNet income ÷ Revenue | -2.3% | +35.0% |
| FCF MarginFCF ÷ Revenue | -2.8% | +18.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -146.2% | +169.9% |
Valuation Metrics
ACOG leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $98M | $1.07T |
| Enterprise ValueMkt cap + debt − cash | $32M | $1.11T |
| Trailing P/EPrice ÷ TTM EPS | -5.38x | 49.37x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 30.95x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.71x |
| EV / EBITDAEnterprise value multiple | — | 35.38x |
| Price / SalesMarket cap ÷ Revenue | 9.57x | 16.42x |
| Price / BookPrice ÷ Book value/share | 1.78x | 38.34x |
| Price / FCFMarket cap ÷ FCF | — | 119.31x |
Profitability & Efficiency
LLY leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $-54 for ACOG. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs ACOG's 4/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -54.1% | +101.2% |
| ROA (TTM)Return on assets | -41.8% | +22.7% |
| ROICReturn on invested capital | -32.4% | +41.8% |
| ROCEReturn on capital employed | -38.4% | +46.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 8 |
| Debt / EquityFinancial leverage | — | 1.60x |
| Net DebtTotal debt minus cash | -$66M | $35.3B |
| Cash & Equiv.Liquid assets | $66M | $7.2B |
| Total DebtShort + long-term debt | $0 | $42.5B |
| Interest CoverageEBIT ÷ Interest expense | — | 35.68x |
Total Returns (Dividends Reinvested)
LLY leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LLY five years ago would be worth $51,207 today (with dividends reinvested), compared to $8,873 for ACOG. Over the past 12 months, LLY leads with a +40.3% total return vs ACOG's -34.4%. The 3-year compound annual growth rate (CAGR) favors LLY at 37.2% vs ACOG's -3.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -3.1% | +5.2% |
| 1-Year ReturnPast 12 months | -34.4% | +40.3% |
| 3-Year ReturnCumulative with dividends | -11.3% | +158.2% |
| 5-Year ReturnCumulative with dividends | -11.3% | +412.1% |
| 10-Year ReturnCumulative with dividends | -11.3% | +1484.6% |
| CAGR (3Y)Annualised 3-year return | -3.9% | +37.2% |
Risk & Volatility
LLY leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LLY is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than ACOG's 1.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 95.8% from its 52-week high vs ACOG's 54.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 0.53x |
| 52-Week HighHighest price in past year | $11.54 | $1182.73 |
| 52-Week LowLowest price in past year | $4.50 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +54.6% | +95.8% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 70.0 |
| Avg Volume (50D)Average daily shares traded | 42K | 2.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ACOG as "Buy" and LLY as "Buy". Consensus price targets imply 122.2% upside for ACOG (target: $14) vs 12.0% for LLY (target: $1269). LLY is the only dividend payer here at 0.53% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $14.00 | $1268.94 |
| # AnalystsCovering analysts | 1 | 45 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% |
| Dividend StreakConsecutive years of raises | — | 11 |
| Dividend / ShareAnnual DPS | — | $6.00 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
LLY leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACOG leads in 1 (Valuation Metrics).
ACOG vs LLY: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is ACOG or LLY a better buy right now?
Eli Lilly and Company (LLY) offers the better valuation at 49.
4x trailing P/E (30. 9x forward), making it the more compelling value choice. Analysts rate Alpha Cognition Inc. Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACOG or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.
1%, compared to -11. 3% for Alpha Cognition Inc. Common Stock (ACOG). Over 10 years, the gap is even starker: LLY returned +1485% versus ACOG's -11. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACOG or LLY?
By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.
53β versus Alpha Cognition Inc. Common Stock's 1. 29β — meaning ACOG is approximately 144% more volatile than LLY relative to the S&P 500.
04Which is growing faster — ACOG or LLY?
On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96.
0% year-over-year, compared to 42. 1% for Alpha Cognition Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACOG or LLY?
Eli Lilly and Company (LLY) is the more profitable company, earning 31.
7% net margin versus -202. 2% for Alpha Cognition Inc. Common Stock — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -221. 7% for ACOG. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ACOG or LLY more undervalued right now?
Analyst consensus price targets imply the most upside for ACOG: 122.
2% to $14. 00.
07Which pays a better dividend — ACOG or LLY?
In this comparison, LLY (0.
5% yield) pays a dividend. ACOG does not pay a meaningful dividend and should not be held primarily for income.
08Is ACOG or LLY better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
53), 0. 5% yield, +1485% 10Y return). Both have compounded well over 10 years (LLY: +1485%, ACOG: -11. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ACOG and LLY?
These companies operate in different sectors (ACOG (Financial Services) and LLY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ACOG is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock. LLY pays a dividend while ACOG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.